Toviaz (fesoterodine fumarate), manufactured by Schwarz Pharma of Zwickau, Germany, and distributed by Pfizer, has been approved to help patients suffering from overactive bladder (OAB).
PARIS—The severity of a patient’s overactive bladder (OAB) symptoms prior to treatment with fixed-dose darifenacin (Enablex) has no effect on treatment response, researchers announced here at the Fourth International Consultation on Incontinence.
Antibody responses could explain why some patients fail botulinum toxin type A (BoNT/A) treatment of hyperactive detrusor or sphincter dysfunction, according to German investigators.
Sanctura XR (trospium chloride extended-release capsules), made by Indevus Pharmaceuticals, Inc., of Lexington, Mass., has been approved for the once-daily treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
The cardinal symptoms of overactive bladder (OAB)—urinary urgency, frequency, and urge urinary incontinence—are not significantly associated with detrusor overactivity after adjustment for other risk factors, a study found.